PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
A proprietary aqueous extract (Phase 2 WKBE) significantly reduced body weight, fat mass, BMI, and waist and hip circumference in a dose-dependent manner over 12 weeks [PMID:38830962].
Clinical and preclinical evidence suggests potential for weight regulation, suppression of starch digestion, attenuation of postprandial glycemia, and hypolipidemic effects [PMID:41300098].
Safety & adverse effects
Dosage & administration
Evidence summary
PubMed sources
- 1.PMID: 38830962 (2024) — Proprietary alpha-amylase inhibitor formulation from white kidney bean (Phaseolus vulgaris L.) promotes weight and fat loss: a 12-week, double-blind, placebo-controlled, randomized trial. · Scientific reports
- 2.PMID: 39459901 (2024) — Interactions between Common Bean Viruses and Their Whitefly Vector. · Viruses
- 3.PMID: 33282144 (2017) — Viruses infecting common bean (Phaseolus vulgaris L.) in Tanzania: A review on molecular characterization, detection and disease management options. · African journal of agricultural research
- 4.PMID: 32314065 (2020) — The promiscuity of Phaseolus vulgaris L. (common bean) for nodulation with rhizobia: a review. · World journal of microbiology & biotechnology
- 5.PMID: 35485365